Ftse Mib
37.977,59
0,18%
DAX
22.513,42
-0,43%
S&P 500
6.114,63
-0,01%
NASDAQ
20.026,77
0,41%
Bitcoin
97.014,23
-0,59%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. AMEX Matinas Biopharma Holdings Inc (MTNB) Matinas Biopharma Holdings Inc (MTNB) Notizie

Matinas Biopharma Holdings Inc

MTNB
0,585
-0,015 (-2,50%)
15 Feb 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: AMEX
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
13/2/202523:20EDGAR2Form 8-K - Current report
13/2/202523:00GLOBEMatinas BioPharma Announces Agreement for the Acquisition of..
11/2/202523:10EDGAR2Form 8-K - Current report
07/2/202513:30EDGAR2Form 8-K - Current report
07/2/202513:30GLOBEMatinas BioPharma Appoints Evelyn D’An to Board of Directors..
24/1/202523:15EDGAR2Form 8-K - Current report
10/1/202523:15EDGAR2Form 8-K - Current report
10/1/202523:15GLOBEMatinas BioPharma Receives NYSE Noncompliance Notice
06/1/202522:57EDGAR2Form SCHEDULE 13D - General Statement of Acquisition of..
27/11/202423:00EDGAR2Form 8-K - Current report
13/11/202423:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
31/10/202411:31EDGAR2Form 8-K - Current report
31/10/202411:30GLOBEMatinas BioPharma Announces the Termination of MAT2203..
03/9/202414:56EDGAR2Form 8-K - Current report
28/8/202403:39EDGAR2Form 8-K - Current report
20/8/202422:05EDGAR2Form 8-K - Current report
14/8/202422:07EDGAR2Form 8-K - Current report
14/8/202422:05GLOBEMatinas BioPharma Reports Second Quarter 2024 Financial..
14/8/202422:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202413:00GLOBEMatinas BioPharma to Webcast Conference Call to Discuss..
24/6/202414:30GLOBEMatinas BioPharma Reports Successful Treatment of Patient..
13/6/202413:00GLOBEMatinas BioPharma’s Oral MAT2203 to Be Featured in Fireside..
16/5/202413:00GLOBENew In Vitro Data Showing Matinas BioPharma’s LNC Platform..
09/5/202422:06EDGAR2Form 8-K - Current report
09/5/202422:05GLOBEMatinas BioPharma Reports First Quarter 2024 Financial..
09/5/202422:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202414:00GLOBEMatinas BioPharma’s LNC Platform for the Delivery of Small..
02/5/202413:00GLOBEMatinas BioPharma to Webcast Conference Call to Discuss..
30/4/202414:00GLOBEIn Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in..
03/4/202414:30GLOBEMatinas BioPharma Prices $10 Million Registered Direct..
27/3/202421:05GLOBEMatinas BioPharma Reports 2023 Financial Results and..
25/3/202413:00GLOBEMatinas BioPharma Announces Positive in vivo Safety Data..
22/3/202414:15GLOBEThree Patients with Invasive Fusarium Infection in Matinas..
22/3/202411:30GLOBEMatinas BioPharma Regains Compliance with NYSE American..
26/2/202414:05EDGAR2Form 8-K - Current report
26/2/202414:00GLOBEMatinas BioPharma Provides Positive Outcomes Update on the..
20/2/202413:35EDGAR2Form 8-K - Current report
20/2/202413:30GLOBEMatinas BioPharma Successfully Reaches Agreement with FDA..
Apertura: 0,70 Min: 0,59 Max: 0,70
Chiusura: 0,60

La tua Cronologia

AMEX
MTNB
Matinas Biopharma
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci